Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Fosbretabulin (disodium) [168555-66-6]

Fosbretabulin (disodium) [168555-66-6]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-17449-5mg

Size : 5mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Fosbretabulin disodium Chemische Struktur

Fosbretabulin disodium Chemische Struktur

CAS. Nr. : 168555-66-6

This product is a controlled substance and not for sale in your territory.

Beschreibung

Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis[1][3].

IC50 & Target

tubulin[1]
In Vitro

Fosbretabulin disodium inhibits growth of leukemia P-388, pancreas BXPC-3,?neuroblast SK-N-SH, thyroid SW1736, lung-NSC NCI-H460, prostate DU-145, an pharynx FADU, with EC50s of 0.0029, 0.23, 0.00025, 0.00061, 0.00035, 0.00072, and 0.00045 μg/mL, respectively[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Fosbretabulin disodium Related Antibodies
In Vivo

Fosbretabulin disodium (100 mg/kg; i.p.) increases the mean arterial blood pressure (MABP) at 1 and 6 h after administration and decreases the tumor blood flow in rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BD9 rats (7-9 weeks) bearing the s.c. implanted P22 tumor[3]
Dosage: 100 mg/kg
Administration: A single i.p. injections
Result: Significantly raised the MABP by about 30%, and reduced the heart rate at 1 h after administration.
Reduced the blood flow in the tumor.
Klinische Studie
Molekulargewicht

440.29

Formel

C18H19Na2O8P
CAS. Nr.

168555-66-6
Appearance

Solid

Color

White to off-white

SMILES

COC1=C(OC)C(OC)=CC(/C=C\C2=CC=C(OC)C(OP(O[Na])(O[Na])=O)=C2)=C1
Structure Classification
  • Stilbenes
Initial Source
  • Plants
  • other families
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit
In Vitro: 

H2O : 4.5 mg/mL (10.22 mM; Need ultrasonic and warming)

DMF : < 1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2712 mL 11.3562 mL 22.7123 mL
5 mM 0.4542 mL 2.2712 mL 4.5425 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molaritätsrechner

  • Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 14.29 mg/mL (32.46 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Reinheit & Dokumentation

Purity: 99.47%

COA (265 KB) HNMR (165 KB) LCMS (394 KB)

Handling Instructions (2659 KB)
Verweise

  • [1]. Shen CH, et, al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 2010 Aug;160(8):2008-27.  [Content Brief]

    [2]. Pettit GR, et, al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41. J Med Chem. 2005 Jun 16;48(12):4087-99.  [Content Brief]

    [3]. Tozer GM, et, al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999 Apr 1;59(7):1626-34.  [Content Brief]

  • [1]. Shen CH, et, al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 2010 Aug;160(8):2008-27.

    [2]. Pettit GR, et, al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41. J Med Chem. 2005 Jun 16;48(12):4087-99.

    [3]. Tozer GM, et, al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999 Apr 1;59(7):1626-34.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 2.2712 mL 11.3562 mL 22.7123 mL 56.7808 mL
5 mM 0.4542 mL 2.2712 mL 4.5425 mL 11.3562 mL
10 mM 0.2271 mL 1.1356 mL 2.2712 mL 5.6781 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Fosbretabulin disodium Related Classifications

  • Cell Cycle/DNA Damage Cytoskeleton Apoptosis
  • Microtubule/Tubulin Apoptosis
Help & FAQs

Keywords:

Fosbretabulin disodium168555-66-6CA 4DP CA 4PCombretastatin A4 disodiumMicrotubule/TubulinApoptosistubulindestabilizingendothelianascenttumourneovesselsInhibitorinhibitorinhibit

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
HY-16366-1mg
Briciclib [865783-99-9]
 1mg 
HY-10223-5mg
CUDC-101 [1012054-59-9]
 5mg 
HY-11003-5mg
GW843682X [660868-91-7]
 5mg